Chimeric Therapeutics Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Public

  • Employees
  • 19

Employees

  • Stock Symbol
  • CHM

Stock Symbol

Chimeric Therapeutics General Information

Description

Chimeric Therapeutics Ltd is an Australian clinical-stage cell therapy company focused on developing and commercialising a range of cell therapies in oncology. The group's products under development include T Cell Derived Autologous Therapies and Natural Killer (NK) Cell Derived Allogenic Therapies. T Cell Derived Autologous therapy works by engineering the T cells with the exact coordinates to attack and kill cancer. NK Cell Derived Allogenic Therapies from healthy donors can be manufactured on a large scale and, once administered, kill cancer. Its pipeline products include CDH17, CLTX, and CORE NK. The group has one reportable segment, being the research, development, and commercialisation of health technologies.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 62 Lygon Street, Level 3
  • Carlton, Victoria 3053
  • Australia
+61 (03)
Primary Industry
Drug Discovery
Stock Exchange
ASX
Corporate Office
  • 62 Lygon Street, Level 3
  • Carlton, Victoria 3053
  • Australia
+61 (03)

Chimeric Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Chimeric Therapeutics Stock Performance

As of 30-Sep-2026, Chimeric Therapeutics’s current market cap is $248K with 118M shares.

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$248K 118M 1.6M

Chimeric Therapeutics Financials Summary

As of 30-Sep-2026, Chimeric Therapeutics has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2026 FY 2026 30-Jun-2026 FY 2025 30-Jun-2025 FY 2024 30-Jun-2024
EV 164 725 1,955 9,130
Revenue 2,568
EBITDA (5,904) (7,408)
Net Income (6,749) (8,211)
Total Assets 14,090 10,209
Total Debt 0 2,403
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Chimeric Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Chimeric Therapeutics‘s full profile, request access.

Request a free trial

Chimeric Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Chimeric Therapeutics Ltd is an Australian clinical-stage cell therapy company focused on developing and commercialising
Drug Discovery
Carlton, Australia
19 As of 2023

Waltham, MA
 

South San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Chimeric Therapeutics Competitors (47)

One of Chimeric Therapeutics’s 47 competitors is Mustang Bio, a Formerly VC-backed company based in Waltham, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Mustang Bio Formerly VC-backed Waltham, MA
Allogene Therapeutics Formerly VC-backed South San Francisco, CA
Denali Therapeutics Formerly VC-backed South San Francisco, CA
Arovella Therapeutics Corporation Preston, Australia
Fate Therapeutics Formerly VC-backed San Diego, CA
You’re viewing 5 of 47 competitors. Get the full list »

Chimeric Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Chimeric Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Chimeric Therapeutics‘s full profile, request access.

Request a free trial

Chimeric Therapeutics ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Chimeric Therapeutics’s complete esg history, request access »

Chimeric Therapeutics FAQs

  • When was Chimeric Therapeutics founded?

    Chimeric Therapeutics was founded in 2015.

  • Where is Chimeric Therapeutics headquartered?

    Chimeric Therapeutics is headquartered in Carlton, Australia.

  • What is the size of Chimeric Therapeutics?

    Chimeric Therapeutics has 19 total employees.

  • What industry is Chimeric Therapeutics in?

    Chimeric Therapeutics’s primary industry is Drug Discovery.

  • Is Chimeric Therapeutics a private or public company?

    Chimeric Therapeutics is a Public company.

  • What is Chimeric Therapeutics’s stock symbol?

    The ticker symbol for Chimeric Therapeutics is CHM.

  • What is the current market cap of Chimeric Therapeutics?

    The current market capitalization of Chimeric Therapeutics is $248K.

  • Who are Chimeric Therapeutics’s competitors?

    Mustang Bio, Allogene Therapeutics, Denali Therapeutics, Arovella Therapeutics, and Fate Therapeutics are some of the 47 competitors of Chimeric Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process